Defence Therapeutics, a biotech company, announced strategic updates under new CEO Dr. Amie Phinney, focusing on advancing its proprietary Accum® drug-delivery technology to enhance cancer treatments. The company plans to develop partnerships to improve antibody-drug conjugates (ADCs) and accelerate its radiotherapeutics program, while reassessing its clinical-stage AccuTOX® melanoma treatment. With strengthened leadership and recent capital raises, Defence aims to generate revenue through collaborations and licensing, reinvesting in innovative drug delivery applications. Over the next year, the company will prioritize new ADC collaborations, radiotherapeutics development, and defining the future of AccuTOX® to drive growth and shareholder value.
Spain's largest crypto exchange Bit2Me has created Bit2Shield, a new company to assist courts, police, and financial institutions in tracing, seizing, storing, and liquidating cryptocurrency involved in investigations. Bit2Shield will hold seized cry...
Brightstar Lottery PLC announced a tender offer to buy back its €500 million 2.375% Senior Secured Notes due 2028, offering €990 per €1,000 plus accrued interest. Concurrently, Brightstar is issuing new euro-denominated senior secured notes due 2032 ...
The Ethereum Foundation announced a roadmap targeting a fully quantum-resistant Ethereum Layer 1 by December 2029. This upgrade will protect Ethereum's core systems—execution, consensus, and data—from potential quantum computing threats expected arou...
The analyst maintains a buy recommendation on long-term bonds IEF and TLT, citing a cooling economy with declining manufacturing activity and new orders. Inflation is expected to ease, driven by AI-related cost savings and anticipated energy price re...
Solana will implement its Transaction v1 upgrade on September 9, increasing the maximum transaction size from 1,232 bytes to 4,096 bytes. This change allows more complex operations like zero-knowledge proofs and multisignature transactions to fit int...
